The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
Part of paid clinical trials in La Jolla, California.
- Sponsor
- Neurolief Ltd.
- Study ID
- NCT04279522
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Relivion®DP- Active — DEVICERelivion®DP- Active stimulation device
- Relivion®DP- Sham — DEVICERelivion®DP- Sham stimulation device
Study Details
The MOOD study will evaluate the safety and efficacy of a noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP). This is a prospective, multi-center, 2-arm randomized, double-blind, parallel-group, sham-controlled study. The study will include the following stages: 1. Screening, Eligibility evaluation and Randomization to Relivion®DP vs. Sham control (1:1 randomization) (Baseline - Day 0). 2. Daily treatment period: Active/Sham (Group A/B) treatment protocol (Baseline to end of 8 weeks). 3. Open label phase: Active treatment period of additional 8 weeks. After completion of the open label period the subject's participation in the study will be over.
Key Dates
- Start date
- Aug 31, 2021
- Status verified
- Jul 2025
- Primary completion
- Jun 7, 2024
- Completion
- Jun 7, 2024
Study Design
- Enrollment
- 124 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1 - active stimulation
- Placebo Comparator: Group 2 - sham stimulation
Primary Outcome Measure
Mean Change in Depressive Symptoms, Measured by HDRS17 Total Score [ Time Frame: 8 weeks from treatment initiation ]
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Kadima Neuropsychiatry Institute | La Jolla | California | 92037 | - |
| UCLA Semel Institute for Neuroscience and Behaviour | Los Angeles | California | 90024 | - |
| San Marcus Research Clinic | Miami Lakes | Florida | 33014 | - |
| K2 Medical Research Tampa | Tampa | Florida | 33607 | - |
| Northwestern University, Feinberg School of Medicine | Chicago | Illinois | 60611 | - |
| Sheppard Prat Health system | Baltimore | Maryland | 21204 | - |
| University of Minnesota | Minneapolis | Minnesota | 55416 | - |
| University of North Carolina, Department of Psychiatry | Chapel Hill | North Carolina | 27514 | - |
| Butler Hospital/Brown University | Providence | Rhode Island | 02906 | - |
| VA Providence Healthcare System | Providence | Rhode Island | 02908 | - |
| MUSC Institute of Psychiatry | Charleston | South Carolina | 29425 | - |
| Brain Health Consultants and TMS Center | Houston | Texas | 77046 | - |
Find similar trials in La Jolla, CA
Related Studies
- Psilocybin rTMS for Treatment Resistant DepressionPHASE2 · Recruiting · University of Texas at Austin · Austin, Texas
- Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness RegistryEnrolling By Invitation · Biomedical Discoveries and Neuroscientific Foundations LLC · Encinitas, California
- Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive DisorderEnrolling By Invitation · University of California, Los Angeles · Los Angeles, California
- Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in AdolescentsRecruiting · University of Alabama at Birmingham · Birmingham, Alabama